ALKSCIK 1520262

Alkermes plc.

EDGAR filings

Customers

1 active

Suppliers

None disclosed

Largest customer

17%

CAH · FY to 2025-12-31

Named-customer revenue

$250.9M

1 customer · FY to 2025-12-31

Latest period

Dec 31, 2025

10-K filed 2026-02-25

Band height is the estimated dollar value: the disclosed share × the discloser's revenue for that period (latest full year where available). Thin bands are named without a figure. Click a band to open its filing.

Customers 2

Companies ALKS discloses as major customers, as a share of ALKS revenue. 1 active, 1 lapsed.

Company	% of ALKS revenue	Est. revenue	Period	Trend	Status	Source
CAH Distributor CARDINAL HEALTH INC	17%	$250.9M	FY 2025-12-31	−2.0pp	Active	10-K 2026-02-25
The following represents revenue and receivables from the Company’s customers exceeding 10% of the total in each category as of, and for the years ended, December 31, 2025, 2024 and 2023: Year Ended December 31, 2025 2024 2023 Customer Receivables Revenue Receivables Revenue Receivables Revenue McKesson 33 % 31 % 36 % 25 % 14 % 14 % Cencora 26 % 20 % 17 % 15 % 16 % 12 % Cardinal Health 17 % 17 % 16 % 19 % 24 % 20 % Janssen 12 % * 14 % 17 % 23 % 31 % Biogen * * * 11 % * 11 % * Indicates the revenues or receivables for the customer did not exceed 10% of the Company’s total in each category as of or for the years ended December 31, 2025, 2024 and 2023, as noted. 10-K filed 2026-02-25 Period FY 2025-01-01 to 2025-12-31 (17%), FY 2024-01-01 to 2024-12-31 (19%), FY 2023-01-01 to 2023-12-31 (20%)Accession 0001193125-26-068925
BIIB BIOGEN INC.	11%	$171.3M	FY 2024-12-31	±0.0pp	Lapsed Last seen 2024-12-31	10-K 2026-02-25
The following represents revenue and receivables from the Company’s customers exceeding 10% of the total in each category as of, and for the years ended, December 31, 2025, 2024 and 2023: Year Ended December 31, 2025 2024 2023 Customer Receivables Revenue Receivables Revenue Receivables Revenue McKesson 33 % 31 % 36 % 25 % 14 % 14 % Cencora 26 % 20 % 17 % 15 % 16 % 12 % Cardinal Health 17 % 17 % 16 % 19 % 24 % 20 % Janssen 12 % * 14 % 17 % 23 % 31 % Biogen * * * 11 % * 11 % * Indicates the revenues or receivables for the customer did not exceed 10% of the Company’s total in each category as of or for the years ended December 31, 2025, 2024 and 2023, as noted. 10-K filed 2026-02-25 Period FY 2024-01-01 to 2024-12-31 (11%), FY 2023-01-01 to 2023-12-31 (11%)Accession 0001193125-26-068925

Alerts are coming

Get an email when ALKS's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.